New Treatments for Maternal Mental Health Conditions

Several companies and organizations are investigating new ways to treat maternal mental health conditions. Here is a brief update on several promising new therapies.

BREXANOLONE

Lipocine is a biopharmaceutical company that recently completed Phase III clinical trials evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. Nineteen clinical sites across the United States participated in this trial. Treatment is only 48 hours and can be done at home.

LEARN MORE

LUVESILOCIN

In February, Reunion Neuroscience announced completion of the first randomized controlled trial of luvesilocin, a psychedelic agent evaluated for the treatment of postpartum depression.

In addition, the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for luvesilocin. The Breakthrough Therapy Designation aims to expedite the development and review of drugs that treat serious or life-threatening conditions, provides eligibility for Fast Track designation features, and offers enhanced FDA guidance and increased engagement with senior FDA leadership.

LEARN MORE

PSTAIR — Calling all military-connected mothers!

PSTAIR is a cutting-edge, evidence-based program that aims to improve and increase parenting skills. Parents will learn how to regulate strong emotions, develop coping strategies, reduce mental health symptoms, and improve relationships.

A new study is seeking participants, including mothers who are service members, veterans, or spouses of service members or veterans.

LEARN MORE

SAINT® TMS

SAINT® (Stanford Accelerated Intelligent Neuromodulation Therapy) is a rapid, intensive form of transcranial magnetic stimulation (TMS), which is a noninvasive, outpatient procedure that uses magnetic pulses to stimulate nerve cells in the brain to improve symptoms of depression, obsessive-compulsive disorder, and other conditions. Learn more about TMS.

A new study is examining the ability of SAINT to treat postpartum depression. Researchers are recruiting study participants at locations in Massachusetts, New York City, South Carolina, and Texas.

LEARN MORE

ZURZUVAE®

In February, the makers of Zurzuvae® (a 14-day oral treatment for postpartum depression, PPD) launched a direct-to-consumer television commercial featuring a treatment for postpartum depression.

The goal of this campaign is to help bring postpartum depression into the broader public conversation; thereby reducing isolation, increasing awareness, and encouraging women to speak with a healthcare provider about their symptoms and—if diagnosed with postpartum depression—to access treatment.

WATCH THE COMMERCIAL

Tweet